|
|
Line 7: |
Line 7: |
| *“Use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden compared with the rest of Europe [where snus is, inexplicably, banned].” | | *“Use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden compared with the rest of Europe [where snus is, inexplicably, banned].” |
| *Citation: Clarke, E., Thompson, K., Weaver, S. et al. Snus: a compelling harm reduction alternative to cigarettes. Harm Reduct J 16, 62 (2019). doi:10.1186/s12954-019-0335-1 | | *Citation: Clarke, E., Thompson, K., Weaver, S. et al. Snus: a compelling harm reduction alternative to cigarettes. Harm Reduct J 16, 62 (2019). doi:10.1186/s12954-019-0335-1 |
| *Acknowledgement: The review was funded by Imperial Brands Plc.
| |
| <br> | | <br> |
|
| |
|